FR2629717B1 - Preparation de vaccin - Google Patents

Preparation de vaccin

Info

Publication number
FR2629717B1
FR2629717B1 FR8904668A FR8904668A FR2629717B1 FR 2629717 B1 FR2629717 B1 FR 2629717B1 FR 8904668 A FR8904668 A FR 8904668A FR 8904668 A FR8904668 A FR 8904668A FR 2629717 B1 FR2629717 B1 FR 2629717B1
Authority
FR
France
Prior art keywords
vaccine preparation
vaccine
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR8904668A
Other languages
English (en)
Other versions
FR2629717A1 (fr
Inventor
Tamura Shinichi
Kurata Takeshi
Aizawa Chikara
Nagamine Takashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kitasato Institute
Korea National Institute of Health
Original Assignee
Kitasato Institute
Korea National Institute of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kitasato Institute, Korea National Institute of Health filed Critical Kitasato Institute
Publication of FR2629717A1 publication Critical patent/FR2629717A1/fr
Application granted granted Critical
Publication of FR2629717B1 publication Critical patent/FR2629717B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR8904668A 1988-04-08 1989-04-10 Preparation de vaccin Expired - Fee Related FR2629717B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8669388 1988-04-08
JP1006759A JP2849632B2 (ja) 1988-04-08 1989-01-13 ワクチン製剤

Publications (2)

Publication Number Publication Date
FR2629717A1 FR2629717A1 (fr) 1989-10-13
FR2629717B1 true FR2629717B1 (fr) 1994-02-18

Family

ID=26340964

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8904668A Expired - Fee Related FR2629717B1 (fr) 1988-04-08 1989-04-10 Preparation de vaccin

Country Status (7)

Country Link
US (1) US5182109C1 (fr)
JP (1) JP2849632B2 (fr)
KR (1) KR960003378B1 (fr)
CA (1) CA1335571C (fr)
DE (1) DE3911442C2 (fr)
FR (1) FR2629717B1 (fr)
GB (1) GB2217600B (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US6413523B1 (en) * 1989-06-02 2002-07-02 The United States Of America As Represented By The Secretary Of The Navy Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use
DK0482076T3 (da) * 1989-07-14 1995-07-17 American Cyanamid Co Stabile vaccinepræparater indeholdende interleukiner
US5462734A (en) * 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US6232116B1 (en) * 1991-02-15 2001-05-15 University Of Alabama At Birmingham Research Foundation Oral administration of pneumococcal antigens
US6027734A (en) * 1991-02-15 2000-02-22 Uab Research Foundation Mucosal administration of pneumococcal antigens
US6231870B1 (en) * 1995-06-02 2001-05-15 Uab Research Foundation Oral administration of pneumoccal antigens
US6042838A (en) * 1991-02-15 2000-03-28 Uab Research Foundation immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
US5506129A (en) * 1991-05-24 1996-04-09 Evans Medical Limited Virus production
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
WO1994006465A1 (fr) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Antigene de la proteine m hybride et porteur destine au vaccin anti-streptococcique du groupe a
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US5527770A (en) * 1993-08-06 1996-06-18 International Gene Group, Inc. Immunotherapeutic agent derived from bacteria
DK0725653T3 (da) * 1993-10-05 2004-10-11 Celltech Pharmaceuticals Ltd Vaccinepræparater
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US5798260A (en) * 1994-06-24 1998-08-25 Children's Hospital And Medical Center Escherichia coli O157:H7 epithelial adhesin
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6436407B1 (en) 1994-08-26 2002-08-20 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic adjuvant
US5759992A (en) * 1994-08-31 1998-06-02 David Platt Immunotherapeutic agent derived from bacteria and method for its manufacture
DE19521705C2 (de) * 1995-06-14 1997-10-09 Immuno Ag Immunogenes Konstrukt, Verfahren zu dessen Herstellung und Verwendung als Vakzine
US5919463A (en) * 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
EP0837692B1 (fr) * 1995-07-07 2000-08-30 Oravax, Inc. Toxines et toxoides de clostridium difficile utilisees comme adjuvants agissant sur les muqueuses
NZ312876A (en) * 1995-07-07 2000-06-23 Oravax Inc Intranasal, muscosal and systemic vaccination against C. difficile inducing a mucosal immune response in the gastrointestinal and/or genitourinary tracts
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
AU6044598A (en) * 1997-01-29 1998-08-18 The Administrators Of The Tulane Eductional Fund Mutant enterotoxin effective as a non-toxic adjuvant for hiv
WO1998033520A1 (fr) * 1997-02-05 1998-08-06 Bystryn Jean Claude Liposomes sensibles au ph et autres types de vaccins encapsules contenant des immunomodulateurs, et procedes de production et d'utilisation
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
WO1998045324A1 (fr) * 1997-04-04 1998-10-15 The Uab Research Foundation Utilisation des mutants de la toxine du cholera comme adjuvants muqueux
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
EP0919243A1 (fr) * 1997-11-25 1999-06-02 Duphar International Research B.V Vaccin dont l'adjuvant est constitué de sous-unités B de l'entérotoxine thermolabile (LTB) d'Escherichia coli
US20030211122A1 (en) * 1998-02-27 2003-11-13 Innoventus Project Ab Mucosal microparticle conjugate vaccine
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
KR20010043441A (ko) * 1998-05-08 2001-05-25 더 유니버시티 오브 브리스톨 백신용 면역조절제
AU770498B2 (en) 1998-06-19 2004-02-26 Merieux Oravax LT and CT in parenteral immunization methods against helicobacter infection
US6713073B1 (en) 1998-07-24 2004-03-30 Megan Health, Inc. Method of vaccination of newly hatched poultry
EP1123711B9 (fr) * 1998-10-21 2009-08-12 The Kitasato Institute Toxines atténuées comme un adjuvant
ATE290012T1 (de) * 1998-10-21 2005-03-15 Univ Kansas Ct For Res Inc Methode für die herstellung von gereinigtem invasinprotein und seine anwendung
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
US20030180351A1 (en) * 1998-11-06 2003-09-25 Reinhard Gluck Pharmaceutically active composition and dispensing device
DE19851282A1 (de) * 1998-11-06 2000-05-11 Schweiz Serum & Impfinst Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten
AU4188100A (en) * 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US7572466B1 (en) * 1999-10-13 2009-08-11 Health Research, Inc. Oral immunology using plant product containing a non-enteric pathogen antigen
US7527810B1 (en) * 1999-10-13 2009-05-05 Health Research, Inc. Oral immunology using plant product containing hepatitis surface antigen
ATE279944T1 (de) * 1999-12-15 2004-11-15 Secr Defence Brit Kombinationsimpfstoff zur steigerung der immunität gegen brucellose
US20040009185A1 (en) * 2000-01-05 2004-01-15 Peter Emtage Enhancing the immune response to an antigen by presensitzing with an inducing agent prior to immunizing with the agent and the antigen
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
DE60125986T3 (de) * 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7063852B2 (en) 2000-05-19 2006-06-20 The Administrators Of The Tulane Educational Fund Hybrid LT-A/CT-B holotoxin for use as an adjuvant
US7527802B2 (en) * 2001-02-13 2009-05-05 The United States Of America As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
US20040109869A1 (en) * 2001-03-19 2004-06-10 Iomai Corporation Transcutaneous immunostimulation
US20020177614A1 (en) * 2001-03-23 2002-11-28 Merril Carl R. Methods for treating nuerodegenerative diseases including alzheimer's
CN1541111A (zh) * 2001-06-07 2004-10-27 ���Ͽع����޹�˾ 作为佐剂的霍乱全毒素的突变形式
EP1404368B1 (fr) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Formes mutantes de l'holotoxine du cholera en tant qu'adjuvant
EP1371374A1 (fr) * 2002-06-10 2003-12-17 Stefan Prof. Dr. Endres Immunothérapie des infections chroniques et des maladies malignes
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
EP1581256A4 (fr) * 2002-11-14 2006-06-07 Pfizer Prod Inc Utilisation de rmlt en tant qu'antigene marqueur pour vaccins et en tant qu'adjuvant synergetique avec amphigen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BRPI0414073A (pt) 2003-09-02 2006-10-24 Glaxosmithkline Biolog Sa método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
EP1708744A4 (fr) * 2003-12-09 2009-07-15 Intercell Usa Inc Exotoxines deficientes en liaison a gm1 destinees a etre utilisees en tant qu'immuno-adjuvants
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP2772267B1 (fr) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Compositions immunogènes et procédés
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA3207612A1 (fr) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Sequences et vaccins antigeniques composites
WO2016183292A1 (fr) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Procédés rapides pour l'extraction d'acides nucléiques provenant d'échantillons biologiques
US10548970B2 (en) 2015-10-05 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rotavirus G9P[6] strain and use as a vaccine
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA943459A (en) * 1968-12-16 1974-03-12 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4172126A (en) * 1976-11-08 1979-10-23 Sankyo Company Limited Method for the inactivation of microbial toxins and attenuation of vaccines
DE3269054D1 (en) * 1981-06-22 1986-03-27 Univ Rochester Composition of a novel immunogen for protection against diarrheal disease caused by enterotoxigenic escherichia coli
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4440748A (en) * 1982-04-03 1984-04-03 Merck & Co., Inc. Strain of Escherichia coli by bacterial conjugation
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
IL69558A (en) * 1983-08-23 1988-06-30 Yeda Res & Dev Synthetic cholera vaccine
JPS60197628A (ja) * 1984-03-22 1985-10-07 Eisai Co Ltd マイコプラズマ性肺炎予防治療剤
JPS6176422A (ja) * 1984-09-22 1986-04-18 Chemo Sero Therapeut Res Inst 百日ぜきコンポ−ネントワクチンおよび百日ぜき・ジフテリア・破傷風混合ワクチンの製造方法
CA1340372C (fr) * 1984-07-09 1999-02-02 John D. Clements Production d'une sous-unite d'enterotoxine lt-b d'e. coli
AU5359186A (en) * 1985-01-25 1986-08-13 Population Council, Inc., The Method & product for enhancing circulating antibody response
US4762710A (en) * 1986-06-16 1988-08-09 The United States Of America As Represented By The Department Of Health And Human Services Novel method of preparing toxoid by oxidation and metal ions
CA1337859C (fr) * 1987-04-24 1996-01-02 Masashi Chazono Methode pour la culture de bordetella pertussis permettant d'obtenir l'anatoxine et un vaccin de la coqueluche

Also Published As

Publication number Publication date
JPH02243633A (ja) 1990-09-27
DE3911442A1 (de) 1989-11-02
JP2849632B2 (ja) 1999-01-20
GB8907914D0 (en) 1989-05-24
US5182109A (en) 1993-01-26
KR960003378B1 (ko) 1996-03-09
FR2629717A1 (fr) 1989-10-13
CA1335571C (fr) 1995-05-16
GB2217600A (en) 1989-11-01
GB2217600B (en) 1992-03-25
DE3911442C2 (de) 2002-09-12
KR900011476A (ko) 1990-08-01
US5182109C1 (en) 2001-10-02

Similar Documents

Publication Publication Date Title
FR2629717B1 (fr) Preparation de vaccin
DK272889A (da) Vaccine
DK9089D0 (da) Praeparat til vaccine mod kokcidiose
DK489189D0 (da) Farmaceutisk praeparat
DE69027112D1 (de) Impfstoffzusammensetzung
DK540389D0 (da) Immunstimulerende praeparat
DK189788D0 (da) Vaccine
DK603988D0 (da) Farmaceutisk praeparat
DK633087D0 (da) Konjugeret vaccine
DK336489D0 (da) Farmaceutisk praeparat
DK139388A (da) Farmaceutisk praeparat
DE69025414D1 (de) Vakzin-Zusammensetzung
IT9020593A0 (it) procedimento per la preparazione
ATA321188A (de) Pharmazeutische zubereitung
DK375488D0 (da) Vaccine
DK606288D0 (da) Praeparat
IT1227462B (it) Procedimento di preparazione di 6-ossopenicillanati
DK37589D0 (da) Farmaceutisk praeparat for 4-aroylimidazol-2-oner
BR9007246A (pt) Preparacao de vacinas
DK429589D0 (da) Transdermalt laegemiddelpraeparat
DK343689D0 (da) Herbicidt praeparat
DK138888A (da) Farmaceutisk praeparat
DK638889D0 (da) Farmaceutisk kombinationspraeparat
DK653388D0 (da) Vaccine
DK408189D0 (da) Farmaceutisk praeparat

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20061230